{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T03:58:02Z","timestamp":1790827082530,"version":"4.1.0"},"reference-count":111,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T00:00:00Z","timestamp":1705536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["148361"],"award-info":[{"award-number":["148361"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Reports"],"abstract":"<jats:p>Cytomegalovirus (CMV) infections may increase morbidity and mortality in immunocompromised patients. Until recently, standard antiviral drugs against CMV were limited to viral DNA polymerase inhibitors (val)ganciclovir, foscarnet and cidofovir with a risk for cross-resistance. These drugs may also cause serious side effects. This narrative review provides an update on new antiviral agents that were approved for the prevention and treatment of CMV infections in transplant recipients. Letermovir was approved in 2017 for CMV prophylaxis in CMV-seropositive adults who received an allogeneic hematopoietic stem cell transplant. Maribavir followed four years later, with an indication in the treatment of adult and pediatric transplant patients with refractory\/resistant CMV disease. The target of letermovir is the CMV terminase complex (constituted of pUL56, pUL89 and pUL51 subunits). Letermovir prevents the cleavage of viral DNA and its packaging into capsids. Maribavir is a pUL97 kinase inhibitor, which interferes with the assembly of capsids and the egress of virions from the nucleus. Both drugs have activity against most CMV strains resistant to standard drugs and exhibit favorable safety profiles. However, high-level resistance mutations may arise more rapidly in the UL56 gene under letermovir than low-grade resistance mutations. Some mutations emerging in the UL97 gene under maribavir can be cross-resistant with ganciclovir. Thus, letermovir and maribavir now extend the drug arsenal available for the management of CMV infections and their respective niches are currently defined.<\/jats:p>","DOI":"10.3390\/idr16010005","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T05:46:44Z","timestamp":1705643204000},"page":"65-82","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Management of Cytomegalovirus Infections in the Era of the Novel Antiviral Players, Letermovir and Maribavir"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-0094","authenticated-orcid":false,"given":"Jocelyne","family":"Piret","sequence":"first","affiliation":[{"name":"Centre de Recherche en Infectiologie, CHU de Qu\u00e9bec-Universit\u00e9 Laval, Quebec City, QC G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3027-4662","authenticated-orcid":false,"given":"Guy","family":"Boivin","sequence":"additional","affiliation":[{"name":"Centre de Recherche en Infectiologie, CHU de Qu\u00e9bec-Universit\u00e9 Laval, Quebec City, QC G1V 4G2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,1,18]]},"reference":[{"key":"ref_1","first-page":"1823","article-title":"Herpes simplex viruses","volume":"Volume 2","author":"Knipe","year":"2013","journal-title":"Fields Virology"},{"key":"ref_2","unstructured":"Boivin, G., and Limaye, A.P. (2023). Goldman-Cecil Medicine, Elsevier."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ald\u00e8, M., Binda, S., Primache, V., Pellegrinelli, L., Pariani, E., Pregliasco, F., Di Berardino, F., Cantarella, G., and Ambrosetti, U. (2023). Congenital Cytomegalovirus and Hearing Loss: The State of the Art. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134465"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1086\/528718","article-title":"Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation","volume":"46","author":"Arthurs","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/CMR.00043-19","article-title":"Progress and Challenges in the Prevention, Diagnosis, and Management of Cytomegalovirus Infection in Transplantation","volume":"34","author":"Limaye","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/bs.enz.2021.07.003","article-title":"DNA polymerases of herpesviruses and their inhibitors","volume":"50","author":"Piret","year":"2021","journal-title":"Enzymes"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1182\/blood.V97.2.388","article-title":"Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. The Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation","volume":"97","author":"Ljungman","year":"2001","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1089\/sur.2015.266","article-title":"Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients","volume":"18","author":"Bonatti","year":"2017","journal-title":"Surg. Infect."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e13521","DOI":"10.1111\/tid.13521","article-title":"Outcomes of transplant recipients treated with cidofovir for resistant or refractory cytomegalovirus infection","volume":"23","author":"Alfares","year":"2021","journal-title":"Transpl. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gourin, C., Alain, S., and Hantz, S. (2023). Anti-CMV therapy, what next? A systematic review. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1321116"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/femsre\/fuy004","article-title":"The human cytomegalovirus terminase complex as an antiviral target: A close-up view","volume":"42","author":"Ligat","year":"2018","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2018.11.005","article-title":"Targeting the terminase: An important step forward in the treatment and prophylaxis of human cytomegalovirus infections","volume":"161","author":"Gentry","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/rmv.615","article-title":"Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir","volume":"19","author":"Prichard","year":"2009","journal-title":"Rev. Med. Virol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Steingruber, M., and Marschall, M. (2020). The Cytomegalovirus Protein Kinase pUL97:Host Interactions, Regulatory Mechanisms and Antiviral Drug Targeting. Microorganisms, 8.","DOI":"10.3390\/microorganisms8040515"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.biologicals.2016.04.005","article-title":"A collaborative study to establish the 1st WHO International Standard for human cytomegalovirus for nucleic acid amplification technology","volume":"44","author":"Fryer","year":"2016","journal-title":"Biologicals"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/gast.1996.v111.pm8690210","article-title":"Cytomegalovirus DNA level on biopsy specimens during treatment of cytomegalovirus gastrointestinal disease","volume":"111","author":"Cotte","year":"1996","journal-title":"Gastroenterology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.diagmicrobio.2012.07.006","article-title":"Cytomegalovirus ventriculoencephalitis with compartmentalization of antiviral-resistant cytomegalovirus in a T cell-depleted haploidentical peripheral blood stem cell transplant recipient","volume":"74","author":"Jeong","year":"2012","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Prakash, K., Chandorkar, A., and Saharia, K.K. (2021). Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update. Diagnostics, 11.","DOI":"10.3390\/diagnostics11050875"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1097\/TP.0000000000001825","article-title":"CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor","volume":"101","author":"Schachtner","year":"2017","journal-title":"Transplantation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcv.2018.06.009","article-title":"T-Track-CMV and QuantiFERON-CMV assays for prediction of protection from CMV reactivation in kidney transplant recipients","volume":"105","author":"Gliga","year":"2018","journal-title":"J. Clin. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e12934","DOI":"10.1111\/tid.12934","article-title":"Early viral-specific T-cell testing predicts late cytomegalovirus reactivation following liver transplantation","volume":"20","author":"Sood","year":"2018","journal-title":"Transpl. Infect. Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2018.05.006","article-title":"Analysis of spontaneous resolution of cytomegalovirus replication after transplantation in CMV-seropositive patients with pretransplant CD8+IFNG+ response","volume":"155","author":"Poyato","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1111\/ajt.15315","article-title":"A prospective multicenter observational study of cell-mediated immunity as a predictor for cytomegalovirus infection in kidney transplant recipients","volume":"19","author":"Kumar","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1093\/infdis\/jiw064","article-title":"Utility of the Enzyme-Linked Immunospot Interferon-gamma-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients","volume":"213","author":"Nesher","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1093\/infdis\/jiy592","article-title":"The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients","volume":"219","author":"Shah","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"ofw107","DOI":"10.1093\/ofid\/ofw107","article-title":"Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients","volume":"3","author":"Navarro","year":"2016","journal-title":"Open Forum Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-16-0267-2_1","article-title":"Antiviral Drugs Against Herpesviruses","volume":"1322","author":"Piret","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/358162a0","article-title":"A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells","volume":"358","author":"Sullivan","year":"1992","journal-title":"Nature"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"11447","DOI":"10.1016\/S0021-9258(19)68420-6","article-title":"Inhibition of purified human and herpes simplex virus-induced DNA polymerases by 9-(2-hydroxyethoxymethyl)guanine triphosphate. Effects on primer-template function","volume":"256","author":"Derse","year":"1981","journal-title":"J. Biol. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1073\/pnas.82.8.2473","article-title":"Metabolic activation of the nucleoside analog 9-[(2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus","volume":"82","author":"Biron","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","first-page":"1502","article-title":"Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells","volume":"50","author":"Cihlar","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/AAC.41.3.594","article-title":"Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation","volume":"41","author":"Xiong","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2165\/00003495-199141010-00009","article-title":"Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis","volume":"41","author":"Chrisp","year":"1991","journal-title":"Drugs"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/01.tp.0000226071.12562.1a","article-title":"Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis","volume":"81","author":"Limaye","year":"2006","journal-title":"Transplantation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/TP.0b013e3181bc0301","article-title":"Preemptive versus sequential prophylactic-preemptive treatment regimens for cytomegalovirus in renal transplantation: Comparison of treatment failure and antiviral resistance","volume":"89","author":"Berger","year":"2010","journal-title":"Transplantation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/TP.0b013e318200b9f0","article-title":"Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients","volume":"91","author":"Pascual","year":"2011","journal-title":"Transplantation"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2009.02617.x","article-title":"Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients","volume":"9","author":"Asberg","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0140-6736(00)02607-6","article-title":"Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants","volume":"356","author":"Limaye","year":"2000","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1086\/342385","article-title":"Ganciclovir-resistant cytomegalovirus in organ transplant recipients","volume":"35","author":"Limaye","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk Factors and Outcomes of Ganciclovir-Resistant Cytomegalovirus Infection in Solid Organ Transplant Recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/rmv.1873","article-title":"Human cytomegalovirus antiviral drug resistance in hematopoietic stem cell transplantation: Current state of the art","volume":"26","author":"Campos","year":"2016","journal-title":"Rev. Med. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/338143","article-title":"High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy","volume":"185","author":"Limaye","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1086\/342844","article-title":"Analysis and characterization of antiviral drug-resistant cytomegalovirus isolates from solid organ transplant recipients","volume":"186","author":"Lurain","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.transproceed.2015.09.070","article-title":"Cytomegalovirus Infection and Rates of Antiviral Resistance Following Intestinal and Multivisceral Transplantation","volume":"48","author":"Ambrose","year":"2016","journal-title":"Transplant. Proc."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/tid.12507","article-title":"Resistant cytomegalovirus in intestinal and multivisceral transplant recipients","volume":"18","author":"Timpone","year":"2016","journal-title":"Transpl. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1093\/jac\/dkn521","article-title":"Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem cell transplantation: Implications for the emergence of drug-resistant cytomegalovirus","volume":"63","author":"Allice","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3851\/IMP1899","article-title":"Failure of pre-emptive treatment of cytomegalovirus infections and antiviral resistance in stem cell transplant recipients","volume":"17","author":"Marijt","year":"2012","journal-title":"Antivir. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/infdis\/jit475","article-title":"High rate of cytomegalovirus drug resistance among patients receiving preemptive antiviral treatment after haploidentical stem cell transplantation","volume":"209","author":"Shmueli","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1128\/AAC.42.9.2240","article-title":"Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group","volume":"42","author":"Jabs","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1086\/368385","article-title":"Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis","volume":"187","author":"Weinberg","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1128\/CMR.12.2.286","article-title":"Resistance of human cytomegalovirus to antiviral drugs","volume":"12","author":"Erice","year":"1999","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mayers, D.L., Sobel, J., Ouellette, M., Kaye, K., and Marchaim, D. (2017). Antimicrobial Drug Resistance, Springer. [2nd ed.].","DOI":"10.1007\/978-3-319-46718-4"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1086\/514041","article-title":"High-level resistance of cytomegalovirus to ganciclovir is associated with alterations in both the UL97 and DNA polymerase genes","volume":"176","author":"Smith","year":"1997","journal-title":"J. Infect. Dis."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1128\/AAC.00736-07","article-title":"Growth and drug resistance phenotypes resulting from cytomegalovirus DNA polymerase region III mutations observed in clinical specimens","volume":"51","author":"Chou","year":"2007","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1128\/JCM.01275-13","article-title":"Novel method based on \u201cen passant\u201d mutagenesis coupled with a Gaussia luciferase reporter assay for studying the combined effects of human cytomegalovirus mutations","volume":"51","author":"Drouot","year":"2013","journal-title":"J. Clin. Microbiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1128\/JCM.02205-14","article-title":"Characterization of multiple cytomegalovirus drug resistance mutations detected in a hematopoietic stem cell transplant recipient by recombinant phenotyping","volume":"52","author":"Drouot","year":"2014","journal-title":"J. Clin. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/340101","article-title":"Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients","volume":"34","author":"Mylonakis","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"SOCA (1996). Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaboration with the AIDS Clinical Trials Group. Arch. Ophthalmol., 114, 23\u201333.","DOI":"10.1001\/archopht.1996.01100130021004"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/1521654031000070645","article-title":"Herpes virus replication","volume":"55","author":"Boehmer","year":"2003","journal-title":"IUBMB Life"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/JVI.01955-12","article-title":"The human cytomegalovirus UL51 protein is essential for viral genome cleavage-packaging and interacts with the terminase subunits pUL56 and pUL89","volume":"87","author":"Borst","year":"2013","journal-title":"J. Virol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1128\/JVI.72.3.2259-2264.1998","article-title":"The gene product of human cytomegalovirus open reading frame UL56 binds the pac motif and has specific nuclease activity","volume":"72","author":"Bogner","year":"1998","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"14660","DOI":"10.1128\/JVI.79.23.14660-14667.2005","article-title":"Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides","volume":"79","author":"Dittmer","year":"2005","journal-title":"J. Virol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J. Virol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"6340","DOI":"10.1128\/jvi.70.9.6340-6346.1996","article-title":"The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase","volume":"70","author":"Michel","year":"1996","journal-title":"J. Virol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1128\/AAC.47.7.2186-2192.2003","article-title":"In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses","volume":"47","author":"Williams","year":"2003","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"105328","DOI":"10.1016\/j.antiviral.2022.105328","article-title":"In vitro activity of letermovir against human cytomegalovirus isolates with different drug susceptibility phenotypes","volume":"202","author":"Piret","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cts.12483","article-title":"Intravenous hydroxypropyl beta-cyclodextrin formulation of letermovir: A phase I, randomized, single-ascending, and multiple-dose trial","volume":"10","author":"Kropeit","year":"2017","journal-title":"Clin. Transl. Sci."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: Overview of human cytomegalovirus drug resistance","volume":"163","author":"Piret","year":"2019","journal-title":"Antivir. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/jcph.1094","article-title":"Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects","volume":"58","author":"Marshall","year":"2018","journal-title":"J. Clin. Pharmacol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/cpdd.388","article-title":"Pharmacokinetics and safety of letermovir coadministered with cyclosporine A or tacrolimus in healthy subjects","volume":"7","author":"Kropeit","year":"2018","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40265-017-0860-8","article-title":"Letermovir: First Global Approval","volume":"78","author":"Kim","year":"2018","journal-title":"Drugs"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"ofac687","DOI":"10.1093\/ofid\/ofac687","article-title":"Real-World Outcomes Associated With Letermovir Use for Cytomegalovirus Primary Prophylaxis in Allogeneic Hematopoietic Cell Transplant Recipients: A Systematic Review and Meta-analysis of Observational Studies","volume":"10","author":"Vyas","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.10.019","article-title":"A third component of the human cytomegalovirus terminase complex is involved in letermovir resistance","volume":"148","author":"Chou","year":"2017","journal-title":"Antivir. Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e00922-18","DOI":"10.1128\/AAC.00922-18","article-title":"A new locus of drug resistance in the human cytomegalovirus UL56 gene revealed by in vitro exposure to letermovir and ganciclovir","volume":"62","author":"Chou","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"105361","DOI":"10.1016\/j.antiviral.2022.105361","article-title":"First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure","volume":"204","author":"Muller","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e01325-17","DOI":"10.1128\/AAC.01325-17","article-title":"Comparison of cytomegalovirus terminase gene mutations selected after exposure to three distinct inhibitor compounds","volume":"61","author":"Chou","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"105422","DOI":"10.1016\/j.antiviral.2022.105422","article-title":"Relative frequency of cytomegalovirus UL56 gene mutations detected in genotypic letermovir resistance testing","volume":"207","author":"Chou","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e02337-18","DOI":"10.1128\/AAC.02337-18","article-title":"Use of letermovir as salvage therapy for drug-resistant CMV retinitis: A case series","volume":"63","author":"Turner","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J. Clin. Virol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1128\/JVI.03505-12","article-title":"Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase","volume":"87","author":"Whitehurst","year":"2013","journal-title":"J. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1128\/JVI.77.2.905-914.2003","article-title":"The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress","volume":"77","author":"Krosky","year":"2003","journal-title":"J. Virol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1128\/AAC.46.8.2373-2380.2002","article-title":"Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication","volume":"46","author":"Koszalka","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-022-01677-4","article-title":"Maribavir: First Approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1128\/JVI.01787-07","article-title":"Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant","volume":"82","author":"Chou","year":"2008","journal-title":"J. Virol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2012.05.013","article-title":"Effects on maribavir susceptibility of cytomegalovirus UL97 kinase ATP binding region mutations detected after drug exposure in vitro and in vivo","volume":"95","author":"Chou","year":"2012","journal-title":"Antivir. Res."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Chou, S., Alain, S., Cervera, C., Chemaly, R.F., Kotton, C.N., Lundgren, J., Papanicolaou, G.A., Pereira, M.R., Wu, J.J., and Murray, R.A. (2023). Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients. J. Infect. Dis., jiad293.","DOI":"10.1093\/infdis\/jiad293"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1600-6143.2009.02768.x","article-title":"A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients","volume":"9","author":"Pescovitz","year":"2009","journal-title":"Am. J. Transplant."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: A randomized, dose-ranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1128\/AAC.00114-15","article-title":"In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication","volume":"59","author":"Wildum","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3851\/IMP3028","article-title":"Artesunate demonstrates in vitro synergism with several antiviral agents against human cytomegalovirus","volume":"21","author":"Drouot","year":"2016","journal-title":"Antivir. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.antiviral.2011.07.018","article-title":"The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants","volume":"92","author":"Chou","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1128\/AAC.00577-06","article-title":"Maribavir antagonizes the antiviral action of ganciclovir on human cytomegalovirus","volume":"50","author":"Chou","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2018.07.013","article-title":"Antiviral activity of maribavir in combination with other drugs active against human cytomegalovirus","volume":"157","author":"Chou","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.antiviral.2018.08.015","article-title":"In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus","volume":"158","author":"Markovich","year":"2018","journal-title":"Antivir. Res."},{"key":"ref_106","unstructured":"(2024, January 04). Ganciclovir Prescribing Information. Available online: https:\/\/www.drugs.com\/pro\/ganciclovir.html."},{"key":"ref_107","unstructured":"(2024, January 04). Valganciclovir Prescribing Information. Available online: https:\/\/www.drugs.com\/pro\/valganciclovir.html."},{"key":"ref_108","unstructured":"(2024, January 04). Foscarnet Prescribing Information. Available online: https:\/\/www.drugs.com\/pro\/foscarnet.html."},{"key":"ref_109","unstructured":"(2024, January 04). Cidofovir Injection Prescribing Information. Available online: https:\/\/www.drugs.com\/pro\/cidofovir-injection.html."},{"key":"ref_110","unstructured":"(2024, January 04). Letermovir (Oral\/Injection). Available online: https:\/\/www.drugs.com\/mtm\/letermovir-oral-injection.html."},{"key":"ref_111","unstructured":"(2024, January 04). Maribavir. Available online: https:\/\/www.drugs.com\/mtm\/maribavir.html."}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/16\/1\/5\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:49:14Z","timestamp":1760104154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/16\/1\/5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,18]]},"references-count":111,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["idr16010005"],"URL":"https:\/\/doi.org\/10.3390\/idr16010005","relation":{},"ISSN":["2036-7449"],"issn-type":[{"value":"2036-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,18]]}}}